Join the 'Neo-Decadron Cream' group to help and get support from people like you.
Neo-Decadron Cream News
Posted 6 Oct 2016 by Drugs.com
THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who received a standard drug duo alone. And over 13.5 months, the daratumumab combination cut patients' risk of dying or seeing their cancer progress by 63 percent, the study found. Researchers called the results "unprecedented" for patients like these. All had relapsed or refractory myeloma – which means the cancer had either come back or failed to respond to the previous treatment. "It is very likely that (this regimen) will be rapidly adopted by practicing physicians," said lead researcher Dr. Meletios ... Read more
Related support groups: Dexamethasone, Revlimid, Multiple Myeloma, Decadron, TobraDex, Ciprodex, Maxitrol, Osteolytic Bone Lesions of Multiple Myeloma, Ozurdex, Decadron Tablets, Dexamethasone/Tobramycin, Tobradex ST, Dexamethasone/Neomycin/Polymyxin B, Lenalidomide, Decadron Dose Pack, Dexone, Poly-Dex, Neo-Poly-Dex, Adrenocot LA, Dexpak Taperpak
Posted 25 Nov 2015 by Drugs.com
WEDNESDAY, Nov. 25, 2015 – Patients using prescription creams, gels, sprays and pills for skin conditions may shell out substantially more at the pharmacy than they did just six years ago, a new study suggests. Between 2009 and 2015, retail prices of brand-name dermatologic drugs rose 401 percent, on average, study authors reported Nov. 25 in JAMA Dermatology. Even generics have succumbed to price inflation, up 279 percent between 2011 and 2014, based on the drugs surveyed. Price increases for skin treatments far outpaced the general inflation rate of 11 percent during the six-year study period, the researchers said. "Cancer drugs were the worst in terms of the numbers" – up 1,240 percent or nearly $11,000 over the six-year study period – primarily because of two medicines, said Dr. Steven Rosenberg, voluntary professor of dermatology at the University of Miami Miller School of ... Read more
Related support groups: Monistat, RID, Monistat 3, Eczema, Voltaren Gel, Monistat 7, Dermatitis, Clobetasol, Contact Dermatitis, Bactroban, Mupirocin, Therapeutic, Maintain, Hypercare, Drysol, Sulfur, Fluocinonide, Retin-A, Efudex, Epiduo